About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
ABBV - AbbVie Inc.| Previous Close | $107.33 | Open | $107.68 |
| Volume | 4.01M | Market Cap | 191.934B |
| Yield | 4.37 % | Last Dividend | $4.75 |
| Immunotherapy Drugs Market Analysis By M... | 12:08 AM |
| Immunotherapy Drugs Market Report 2020 added recently by CMI, evaluates the industry in terms of market size, market share, revenue estimation, and ge... | |
| AbbVie's Humira Gets FDA Approval For Pe... | 02/25/21 |
| The FDA has approved AbbVie Inc???s (NYSE: ABBV) Humira (adalimumab) to treat moderately to severely active ulcerative colitis in pediatric patients f... | |
| AbbVie's Humira Gets FDA Approval For Pe... | 02/25/21 |
| The FDA has approved AbbVie Inc's (NYSE: ABBV) Humira (adalimumab) to treat moderately to severely active ulcerative colitis in pediatric ??? | |
| Second Phase 3 Induction Study Confirms ... | 02/22/21 |
| /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted ... | |
| STAT+: AbbVie smooths over a dispute abo... | 02/22/21 |
| After two years of bickering, AbbVie and a marketing partner have settled a dispute in which they had accused two competitors of stealing trade secret... | |
| AbbVie puts an end to Botox trade secret... | 02/19/21 |
| The crown jewel of AbbVie's big-dollar acquisition of Allergan, Botox is one of the most recognizable brands in pharma ??? and both drugmakers have wo... | |
| Global Uveitis treatment Market (2020 to... | 02/18/21 |
| DUBLIN--(BUSINESS WIRE)--The "Global Uveitis treatment Market 2020-2026" report has been added to ResearchAndMarkets.com's offering. The global uveiti... | |
| 4.6% CAGR | Big Boom in Europe Dry Eye P... | 02/18/21 |
| Europe Dry Eye Product Market study by ???The Business Market Insights??? provides details about the market dynamics affecting the market, Market scop... | |
| Psoriasis Drug Market Demand And Future ... | 02/18/21 |
| Psoriasis Drug Market Overview: The market research report on the Global Psoriasis Drug Market offered by Straits Research, analyses the major opportu... | |
| FDA Accepts Coherus Biosciences' Adalimu... | 02/17/21 |
| The FDA has accepted for review Coherus BioSciences Inc's (NASDAQ: CHRS) marketing application for CHS-1420 and AbbVie's ??? | |
| Warren Buffett's Berkshire Cuts Apple St... | 02/16/21 |
| Berkshire Hathaway Inc (NYSE: BRK-A ) (NYSE: BRK-B ) cut its positions in Apple Inc (NASDAQ: AAPL ) and piled on stocks of drug, telecom, and oil comp... | |
| Berkshire Reveals New Positions In Chevr... | 02/16/21 |
| Berkshire Reveals New Positions In Chevron, Verizon; Exits JPM; Trims Apple, Wells: Full 13F Summary Ahead of today's 13F filing by Buffett's Berkshir... | |
| AbbVie shares continue to trade in a bul... | 02/13/21 |
| AbbVie (NYSE: ABBV) shares weakened last week by more than 3%, and the current price stands around $104. According to analysts, it???s not hard to fin... | |
| Cramer's lightning round: AbbVie stock i... | 02/12/21 |
| "Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed. | |
| H2 2020 Melanoma Pipeline Review - Featu... | 02/12/21 |
| DUBLIN--(BUSINESS WIRE)--The "Melanoma - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This report pro... | |
| AbbVie (ABBV) to Present at the 10th Ann... | 02/12/21 |
| AbbVie to Present at the 10th Annual SVB Leerink Global Healthcare Conference??? | |
| Biopharmaceuticals and Biomedicine Marke... | 02/12/21 |
| The global Biopharmaceuticals and Biomedicine Market research report thoroughly explains each and every aspect related to the Biopharmaceuticals and B... | |
| The Horizons Psychedelic Stock Index ETF... | 02/11/21 |
| On January 27, the Horizons Psychedelic Stock Index ETF (NEO:PSYK) became the first exchange traded fund to focus solely on the psychedelics industry.... | |
| Penrose TherapeuTx Appoints Oncology Cli... | 02/11/21 |
| ANN ARBOR, Mich. & CHICAGO--(BUSINESS WIRE)--Penrose TherapeuTx, a pharmaceutical company focused on developing innovative small-molecule therapies fo... | |
| AbbVie (ABBV) and Caribou Biosciences An... | 02/10/21 |
| AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell??? | |
| AbbVie taps Caribou Biosciences for lice... | 02/10/21 |
| ???Off-the-shelf??? CAR-Ts have emerged as a hot-tick??et tar??get in next-gen on??col??o??gy R&D, with Big Phar??mas plac??ing big down pay??ments on... | |
| BOTOX?? (onabotulinumtoxinA) Receives FD... | 02/10/21 |
| /PRNewswire/ -- Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX?? for th... | |
| Antibodies Market - Novartis AG, F. Hoff... | 02/10/21 |
| The Antibodies market demand is anticipated to flourish during the forecast period 2020-2027. The report offers information related to import and expo... | |
| Biologics Market - AbbVie, Amgen, AstraZ... | 02/10/21 |
| The Biologics market demand is anticipated to flourish during the forecast period 2020-2027. The report offers information related to import and expor... | |
| Tumor Necrosis Factor (TNF) Inhibitor Dr... | 02/09/21 |
| The Tumor Necrosis Factor (TNF) Inhibitor Drugs market demand is anticipated to flourish during the forecast period 2020-2027. The report offers infor... | |
| Global Virology Market || Key players Ab... | 02/08/21 |
| Global virology market report published by Prophecy Market Insights offers holistic view of various influencing factors and aims to answer all the tar... | |
| PARP Inhibitor Market Covid19 Impact - A... | 02/08/21 |
| Coherent Market Insights announced that it???s published an exclusive report namely Global PARP Inhibitor Market by Manufacturers, Regions, Type, and ... | |
| Why Infinity Pharma, Meridian Bio, More ... | 02/05/21 |
| Infinity Pharmaceuticals (NASDAQ: INFI ) shares are trading higher Friday after JPMorgan upgraded the stock from Underweight to Neutral. Infinity Phar... | |
| Global Adalimumab, Infliximab and Etaner... | 02/05/21 |
| DUBLIN , Feb. 5, 2021 /PRNewswire/ -- The "Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change"... | |
| Strong Buy rating | 02/04/21 |
| SVB Leerink maintains Outperform rating and raises Price Target from $128.00 to $140.00 | |
| Strong Buy rating | 01/28/21 |
| Morgan Stanley maintains Overweight rating and lowers Price Target from $120.00 to $116.00 | |
| Strong Buy rating | 12/16/20 |
| SVB Leerink maintains Outperform rating and raises Price Target from $119.00 to $128.00 | |
| Strong Buy rating | 11/30/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $108.00 to $120.00 | |
| Date | 2021-02-03 (BMO) | Est. (EPS/Rev.) | $2.85/ 13.7B |
| Actual (EPS/Rev.) | $2.92/ $13.86 B | EPS (TTM) | 5.67 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| OptionIncome | random motion | 95.00 % | Subscribe |
| Option Superstars | James Catzen | 76.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Biotech Fund | Scientia Equity Research | 63.00 % | Subscribe |
| Rocket Investing | Waqas | 59.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
